Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer…
Purple’s innovative immuno-oncology, chemotherapy-free regimen reports encouraging Overall Survival data in 3rd line PDAC patientsRandomized Phase 2 study is enrolling as expected with initial Phase 2 data expected by the end of 2023…